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functioning may become one of the most important clinical
targets in the treatment of schizophrenia.
PMH47
WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY
DURING TREATMENT OF SCHIZOPHRENIA WITH
ANTIPSYCHOTICS AND WITH PLACEBO
Ascher-Svanum H, Stensland MD, Kinon BJ,Tollefson GD
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: To investigate if a) the previously observed link
between weight gain and better clinical response during treat-
ment of schizophrenia has a non-pharmacological component,
and b) if the magnitude of treatment-related weight gain paral-
lels therapeutic effect size across different treatments.
METHODS: We compared olanzapine (N = 187) and placebo
(N = 61) during the ﬁrst 6 weeks of a randomized double-blind
trial in the treatment of schizophrenia. Pearson correlations
assessed the association between weight change and therapeutic
response as measured by BPRS total score. Weight change within
treatment group was contrasted between patients who improved
and those who deteriorated. Analyses were repeated controlling
for treatment duration and baseline weight. RESULTS: Weight
gain was signiﬁcantly correlated with better therapeutic response
for placebo (r = 0.36, p = 0.004) and olanzapine-treated patients
(r = 0.43, p = 0.001). Improved patients gained signiﬁcantly more
weight than patients who deteriorated (p = 0.0001). After 
controlling for treatment duration and baseline weight, every 
1-point improvement on BPRS was associated with 0.056kg
weight gain for olanzapine and 0.089kg weight gain for placebo.
The correlation between therapeutic effect size, per Cochrane’s
meta-analytical reviews, and previously published magnitude of
the corresponding treatment’s weight gain (clozapine, olanzap-
ine, risperidone, haloperidol, placebo) was high and signiﬁcant
(r = 0.91, p = 0.03). CONCLUSIONS: An association between
improvement in psychopathology and greater weight gain was
observed in schizophrenia patients treated with olanzapine and
placebo. Findings suggest that treatment-related weight gain has,
in part, a non-pharmacological basis. Further studies are needed
to evaluate the hypothesis that weight gain, regardless of treat-
ment, is associated with improving psychopathology in schizo-
phrenia patients.
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LIFE AND DISABILITY IN PATIENTS WITH SCHIZOPHRENIA
IN GREECE.THE SQUARE STUDY
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OBJECTIVES: Evaluation of HRQOL has gained increasing
importance in assessing the impact of mental health policies and
the introduction of new neuroleptic drugs. Quetiapine, a new
antipsychotic medication with improved effectiveness, safety and
tolerability proﬁle was introduced in Greece in 2001. The objec-
tive of this study is to assess the HRQOL impact of quetiapine-
based treatment to patients with schizophrenia using a combined
set of outcome measures based on a) psychopathology, b)
HRQOL proﬁles and c) disability scales. METHODS: An open
label, 52-week follow–up study of 170 patients is being con-
ducted in 8 psychiatric hospitals across Greece. Enrolled patients
were diagnosed with mild to moderate schizophrenia (according
to the DSM-IV), aged 18–65, hospitalized or outpatients, newly
diagnosed or in acute exacerbation and assessed at 4 scheduled
visits (baseline, 3-6-12 months). Outcome measures employed
combine psychopathology scales (PANSS, CGI), HRQOL pro-
ﬁles (SF-36, EQ-5D, QLS) and disability indices (WHO-DAS).
All measures are psychometrically and culturally adapted. The
results of 6-month follow-up period are presented in this analy-
sis. RESULTS: Compared to baseline, statistically signiﬁcant
improvements were seen at 6 months in PANSS general psy-
chopathology (48.6 vs. 33.3), positive (23.8 vs.15.2) and nega-
tive symptom (24.3 vs. 17.8) mean scores (p < 0.001). CGI scores
improved from mean level of 5,1 (baseline) to 4,1 (p < 0.001).
All SF-36 dimension scores, especially Role Physical and Role
Emotional were signiﬁcantly improved (p < 0.001). All EQ-5D
dimensions were improved but only the mobility dimension 
and VAS scores showed statistically signiﬁcant improvement 
(p < 0.001). Total and subscale QLS scores were signiﬁcantly
improved except the Instrumental Role Subscale Score (p <
0.001). A statistically signiﬁcant improvement was shown on all
WHO-DAS-II dimensions (p < 0.001). CONCLUSIONS: After
6 months follow-up, quetiapine-treated patients showed a con-
siderable, signiﬁcant improvement in terms of psychopathology
and HRQOL. The combined approach provides for a compre-
hensive assessment of HRQOL impact of new antipsychotic
medications.
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USING CLIENT AND STAFF STRUCTURED INPUT IN
FORMATTING THE SCHIZOPHRENIA OUTCOMES
ASSESSMENT PROJECT (SOAP) SURVEY
Barr J, Schumacher G, Ohman SM, Quimby C
Northeastern University, Boston, MA, USA
OBJECTIVES: Since end-users of surveys may have design
format preferences that are undetected by survey
developer/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-related
quality of life survey for community-residing individuals with
schizophrenia. METHODS: Using cognitive interviews and
visual analogue preference ratings (0–100 scale), we sought 
qualitative and quantitative input from 29 community-residing
clients with schizophrenia and 33 staff members at four sites con-
cerning their preferences for three formats of the 51-item Schiz-
ophrenia Outcomes Assessment Project (SOAP-51) Survey: (i)
6-page booklet with reponses horizontally listed below each
item, (ii) 4-page version with reponses to the right of each item,
and (iii) compressed 2-page version of the former. Survey formats
were presented in randomized order. Staff alsowere asked their
preference for a 4 vs 5 response format. Clients were individu-
ally interviewed in 15–20 minute sessions; staff had individual
(20–30 minute) or group (45–60 minute) sessions. RESULTS:
Clients preferred versions (i) and (ii) over version (iii); respective
VAS values of 70.1, 68.9, and 47.0 (p = 0.012). Qualitatively,
clients indicated the 2-page was too compressed and the 4-page
format made it easier to link the response to the question. Staff
preferred 4/item responses to 5 (84.0 vs 46.1, p < 0.0001)
because they perceived little distinction between 2 of the 5
response levels. Staff had a preference trend toward version (ii)
compared to versions (i) and (iii), 68.6, 58.6, and 58.9, respec-
tively, p = 0.22. When asked their ﬁrst choice, 47%, 34%, and
19% indicated preference for 4-page, 2-page, and booklet ver-
sions, respectively. CONCLUSIONS: Clients preferred booklet
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(i) and 4-page (ii) formats; staff preferred 4-page (ii) and 2-page
(i) formats. Using this, we selected version (ii), 4-page format,
the common preference of both groups. Survey developers
should incorporate end-users to provide insight into format pref-
erences and cognitive processing.
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THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELF-
REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA
DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
Ascher-Svanum H, Zhu B, Faries D, Jiang Q
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: In the treatment of schizophrenia, antiparkin-
sonian agents (APKs) are customarily used to counteract drug-
induced reversible movement disorders such as extrapyramidal
symptoms in order to facilitate adherence to antipsychotic regi-
mens. Unfortunately, in addition to beneﬁcial effects, APKs were
shown to cause other adverse effects such as cognitive impair-
ment. This study prospectively examined the role of APKs in self-
reported medication-related cognitive impairment and akathisia
(subjective or objective restlessness) among patients treated over
a 3-year period in usual care with olanzapine or risperidone.
METHODS: Using data from a 3-year observational study of
schizophrenia, we included olanzapine (N = 372) and risperidone
(N = 229) treated patients who continued on index medication
for at least 1-year post enrollment. Medication use was based 
on medical records. Self-reported medication-related cognitive
impairment and akathisia were assessed with validated instru-
ments. Analysis included mixed models adjusted for covariates.
RESULTS: Utilization rates of APKs were almost twice as high
among risperidone than olanzapine-treated patients (p = 0.001).
When not receiving APKs, akathisia was signiﬁcantly worse for
risperidone than olanzapine-treated patients, and rates of
akathisia were comparable when receiving APKs. However,
when receiving APKs, risperidone-treated patients reported sig-
niﬁcant increases in cognitive impairment compared to olanzap-
ine-treated patients (p = 0.0198). CONCLUSIONS: In this
naturalistic 3-year study, freedom from adjunctive antiparkin-
sonian agents was associated with worse akathsia for risperidone
than olanzapine-treated patients. Moreover, use of antiparkin-
sonian agents was linked to worsening of self-reported cognitive
impairment for risperidone but not for olanzapine-treated




IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE
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Rapaport M3
1CNS Network, Garden Grove, CA, USA; 2Janssen Pharmaceutica
Products, L.P,Titusville, NJ, USA; 3Cedars-Sinai Medical Center, Los
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OBJECTIVE: To evaluate the effect of adjunctive risperidone
treatment on quality of life in patients with treatment-resistant
depression (TRD). METHODS: Data from the open-label treat-
ment phase (4–6 weeks) of an international study designed to
evaluate the efﬁcacy, safety, and maintenance effect of risperi-
done augmentation to SSRI-treatment in TRD. Quality of life
was evaluated using the short form of Quality-of-Life Enjoyment
and Satisfaction Questionnaire (Q-LES-Q). Change in Q-LES-Q
from baseline was analyzed by paired t-test. Correlation analy-
ses between MADRS and Q-LES-Q change scores were per-
formed using Pearson method. RESULTS: This analysis included
386 subjects, mean age 47.1. Baseline and endpoint mean (SD)
Q-LES-Q scores were 42.8 (14.6) and 56.0 (18.6), indicating 
an improvement of 13.2 with risperidone augmentation (P <
0.0001). Signiﬁcant improvements were observed as early as day
7 (P < 0.0001). Q-LES-Q item 15, medication satisfaction, was
rated as good or very good by 61% of subjects. Correlation
between Q-LES-Q and MADRS total change scores at endpoint
was -0.6. CONCLUSIONS: These ﬁndings suggest that aug-
mentation with risperidone rapidly and signiﬁcantly improves
quality of life in TRD patients. Consistent with previous work,
the correlation between Q-LES-Q and MADRS indicate a mean-
ingful relationship between quality of life improvement and
symptom relief.
PMH53
HOSPITALIZATION RATES DURING COMBINATION THERAPY
WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER
Lazarus A1, Lage MJ2, Pesa JA2
1AstraZeneca, Wilmington, DE, USA; 2AstraZeneca LP, Wilmington,
DE, USA
OBJECTIVE: Investigate the effect of atypical antipsychotics
(quetiapine, risperidone, and olanzapine) in combination with a
mood stabilizer on hospitalization rates for bipolar disorder.
METHOD: From the MEDSTAT MarketScan© medical claims
database (1998–2001), 977 individuals were identiﬁed who had
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